Posted by Michael Wonder on 21 Mar 2025
Secretome Therapeutics granted FDA fast track designation for STM-01, a neonatal cardiac progenitor cell therapy for HFpEF
20 March 2025 - Secretome Therapeutics today announced that the US FDA has granted fast track designation to STM-01, the company’s neonatal cardiac progenitor cell therapy, for the treatment of heart failure with preserved ejection fraction.
STM-01, a first in class cellular therapy designed to reduce inflammation, inhibit fibrosis, and support tissue repair in dilated cardiomyopathy and heart failure with preserved ejection fraction.
